AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27793147 — intervention group
Group type: COMPARATOR
Intervention: HIV/STI risk reduction intervention (control condition)
Number of subjects: 107
Study 25704020 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (morning), n = 13
Number of subjects: 40
Study 25704020 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (evening), n = 15
Number of subjects: 40
Study 25704020 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (evening), n = 12
Number of subjects: 40
Study 22539383 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed high-pressure suction drainage
Number of subjects: 120
Study 22539383 — intervention group
Group type: COMPARATOR
Intervention: Presacral drainage
Number of subjects: 120
Study 20567051 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized topical oxygen therapy (TWO(2)), 60-minute treatment, five times per week, pressure cycles between 5 and 50 mb
Number of subjects: 28
Study 20567051 — intervention group
Group type: COMPARATOR
Intervention: Silver-containing dressing, changed at least twice per week (control)
Number of subjects: 28
Study 18404673 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0
Study 18404673 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 18404673 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 0
Study 15892445 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the Short‐Form 36 Health Survey (SF‐36) Physical Functioning (PF)
Number of subjects: 0
Study 15892445 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the Short‐Form 36 Health Survey (SF‐36) Physical Component Summary (PCS)
Number of subjects: 0
Study 15892445 — intervention group
Group type: COMPARATOR
Intervention: English version of the Short‐Form 36 Health Survey (SF‐36) Physical Functioning (PF)
Number of subjects: 0
Study 15892445 — intervention group
Group type: COMPARATOR
Intervention: English version of the Short‐Form 36 Health Survey (SF‐36) Physical Component Summary (PCS)
Number of subjects: 0
Study 12550014 — intervention group
Group type: EXPERIMENTAL
Intervention: BIPAP support pressure device
Number of subjects: 10
Study 12550014 — intervention group
Group type: COMPARATOR
Intervention: Volumetric ventilator
Number of subjects: 10
Study 10485768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume breathing for 3 min at 5 l/min
Number of subjects: 56
Study 10485768 — intervention group
Group type: COMPARATOR
Intervention: Four deep breaths for 30 s at 5 l/min
Number of subjects: 56
Study 10485768 — intervention group
Group type: COMPARATOR
Intervention: Four deep breaths for 30 s at 10 l/min
Number of subjects: 56
Study 10485768 — intervention group
Group type: COMPARATOR
Intervention: Four deep breaths for 30 s at 20 l/min
Number of subjects: 56
Study 10485768 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight deep breaths for 60 s at 10 l/min
Number of subjects: 56
Study 10485768 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique (3 min tidal volume breathing)
Number of subjects: 56
Study 10485768 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea following eight deep breaths technique
Number of subjects: 56
Study 10485768 — intervention group
Group type: COMPARATOR
Intervention: Apnea following traditional technique
Number of subjects: 56
Study 10485768 — intervention group
Group type: COMPARATOR
Intervention: Apnea following four deep breaths technique
Number of subjects: 56
Study 7575750 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 1000 mg/Thioctacid/500 ml NaCl
Number of subjects: 13
Study 7575750 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (500 ml NaCl)
Number of subjects: 13
Study 1838235 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study 1838235 — intervention group
Group type: COMPARATOR
Intervention: Control (no diclofenac)
Number of subjects: 0
Study 1838235 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sterilisation
Number of subjects: 0
Study 1838235 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Number of subjects: 0
Study 1838235 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative side effects
Number of subjects: 0
Study 28545 — intervention group
Group type: EXPERIMENTAL
Intervention: ID-540 (0.5 mg)
Number of subjects: 6
Study 28545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 28545 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Desmethyl-ID-540
Number of subjects: 6
Study 31561819 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly replacement group
Number of subjects: 60
Study 31561819 — intervention group
Group type: COMPARATOR
Intervention: 6-monthly replacement group
Number of subjects: 60
Study 31561819 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 27470115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 µg/kg IV over 10 min before anesthesia induction, followed by 0.7 µg/kg/h infusion during operation
Number of subjects: 50
Study 27470115 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 1 µg/kg IV bolus with induction of anesthesia, continued 0.25-0.50 µg/kg/min during operation
Number of subjects: 50
Study 26245861 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D animated tour of the third ventricle with the DextroBeam
Number of subjects: 169
Study 26245861 — intervention group
Group type: COMPARATOR
Intervention: 2D PowerPoint presentation
Number of subjects: 169
Study 23520223 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard intervention (eight in 12 months) plus treatment as usual
Number of subjects: 0
Study 23520223 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 21628666 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H1N1v vaccine (3.75 μg HA)
Number of subjects: 306
Study 21628666 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted H1N1v vaccine (15 μg HA)
Number of subjects: 306
Study 19398387 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injections with varying volumes
Number of subjects: 15
Study 19398387 — intervention group
Group type: COMPARATOR
Intervention: Epidural injections with the same volume
Number of subjects: 15
Study 19398387 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injections with different volumes
Number of subjects: 15
Study 17303369 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program with pedometer (WPP)
Number of subjects: 369
Study 17303369 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (WP)
Number of subjects: 369
Study 17303369 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group (C)
Number of subjects: 369
Study 14725511 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic haemodilution (ANH)
Number of subjects: 20
Study 14725511 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 11799593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (Reductil‐Abbott Laboratories)
Number of subjects: 0
Study 9489535 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression surgery
Number of subjects: 9
Study 9489535 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and sex matched)
Number of subjects: 9
Study 7908865 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional intravenous nutrition (0.2 g of N and 103 non-protein kJ/kg body weight)
Number of subjects: 0
Study 7908865 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 0
Study 7908865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nutrition enriched with branched-chain amino acids (0.2 g of N with 30% from branched-chain amino acids and 103 non-protein kJ/kg body weight)
Number of subjects: 0
Study 3421250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin prophylaxis (n = 43)
Number of subjects: 82
Study 3421250 — intervention group
Group type: COMPARATOR
Intervention: No ampicillin prophylaxis (n = 39)
Number of subjects: 82
Study 31846901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 38
Study 29655984 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor affordance program at home for infants (G-2)
Number of subjects: 14
Study 29655984 — intervention group
Group type: COMPARATOR
Intervention: Motor affordance program at home for infants (G-1)
Number of subjects: 14
Study 28000689 — intervention group
Group type: EXPERIMENTAL
Intervention: Salba-chia (25g)
Number of subjects: 15
Study 28000689 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax (31.5g)
Number of subjects: 15
Study 28000689 — intervention group
Group type: COMPARATOR
Intervention: Glucose control
Number of subjects: 15
Study 26224039 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy and surgery
Number of subjects: 38
Study 26224039 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 38
Study 26224039 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 38
Study 23193161 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 174
Study 21986137 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous local infiltration analgesia (CLIA)
Number of subjects: 80
Study 21986137 — intervention group
Group type: COMPARATOR
Intervention: Single-injection local infiltration analgesia (SLIA)
Number of subjects: 80
Study 21986137 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study 18800207 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided group (SG) who were given an advance directive (AD) and written instructions
Number of subjects: 59
Study 18800207 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) who were given the same material but offered guidance to complete the AD
Number of subjects: 59
Study 18800207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AD completers)
Number of subjects: 59
Study 18800207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (non-AD completers)
Number of subjects: 59
Study 18800207 — intervention group
Group type: EXPERIMENTAL
Intervention: AD completers
Number of subjects: 59
Study 17986327 — intervention group
Group type: EXPERIMENTAL
Intervention: no added salt diet
Number of subjects: 80
Study 15379315 — intervention group
Group type: EXPERIMENTAL
Intervention: six flavor glutinous rehmannis pill
Number of subjects: 120
Study 11858103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiklid
Number of subjects: 30
Study 11858103 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 30
Study 9020492 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum concentrations of HCG > 1000 IU l(‐1)
Number of subjects: 669
Study 9020492 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum concentrations of AFP > 1000 IU l(‐1)
Number of subjects: 669
Study 9020492 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-lives of HCG > 3 days
Number of subjects: 669
Study 9020492 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-lives of AFP > 6 days
Number of subjects: 669
Study 7885970 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (100 mg ZDV after an 8-hour fast)
Number of subjects: 18
Study 7885970 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (100 mg ZDV with a high-fat breakfast)
Number of subjects: 18
Study 7885970 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C (100 mg ZDV 3 hours after a high-fat breakfast)
Number of subjects: 18
Study 2897986 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of terfenadine and 300 mg of flurbiprofen per day
Number of subjects: 28
Study 2897986 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine and a placebo that looked like flurbiprofen
Number of subjects: 28
Study 31619442 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine 900 mg/day
Number of subjects: 16
Study 31619442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31619442 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine and mesalamine
Number of subjects: 16
Study 30212239 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/day)
Number of subjects: 87
Study 30212239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (5 μg/day)
Number of subjects: 87
Study 30212239 — intervention group
Group type: COMPARATOR
Intervention: No add-on therapy
Number of subjects: 87
Study 28751960 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 1765
Study 28751960 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 1765
Study 26071277 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose (300 mg or 900 mg)
Number of subjects: 106
Study 23668548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized cyclosporine (300 mg of CIS, 62.5 mg/mL CsA in propylene glycol)
Number of subjects: 10
Study 23668548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized cyclosporine with predose coaching
Number of subjects: 10
Study 23668548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized cyclosporine (300 mg of CIS)
Number of subjects: 10
Study 22610907 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise, 3 times per week for 6 months
Number of subjects: 140
Study 22610907 — intervention group
Group type: COMPARATOR
Intervention: General advice about physical activity (Control)
Number of subjects: 140
Study 18831711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 53
Study 18831711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 17572575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg intravenously intraoperatively followed by a 6-day oral tapering dose of methyl-prednisone)
Number of subjects: 48
Study 17572575 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnica (three times a day for 4 days)
Number of subjects: 48
Study 17572575 — intervention group
Group type: COMPARATOR
Intervention: Control group (received neither agent)
Number of subjects: 48
Study 15769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional articulation in UHMWPE acetabular components
Number of subjects: 0
Study 15769535 — intervention group
Group type: COMPARATOR
Intervention: Multidirectional articulation in UHMWPE acetabular components
Number of subjects: 0
Study 15769535 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient gait path analysis
Number of subjects: 0
Study 12034149 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic atrial fibrillation (AF)
Number of subjects: 60
Study 9846713 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cystectomy
Number of subjects: 44
Study 7740468 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 24
Study 7740468 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin
Number of subjects: 24
Study 7740468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7740468 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin plus 100 mg aspirin
Number of subjects: 24
Study 3190989 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim, 200 mg twice daily
Number of subjects: 77
Study 3190989 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin, 250 mg four times daily
Number of subjects: 77
Study 3190989 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 77
Study 29514551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetration items only
Number of subjects: 179
Study 29514551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetration items followed by victimization items
Number of subjects: 179
Study 29514551 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization items followed by perpetration items
Number of subjects: 179
Study 29514551 — intervention group
Group type: COMPARATOR
Intervention: Victimization items only
Number of subjects: 179
Study 31845149 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger Hispanic/Latino and black men having older sex partners (≥50% of partners being at least 5 years older)
Number of subjects: 2665
Study 31845149 — intervention group
Group type: EXPERIMENTAL
Intervention: Not knowing one's HIV status
Number of subjects: 2665
Study 31845149 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a black sex partner
Number of subjects: 2665
Study 29382793 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent monitoring (immediately after intubation, every 8 h, and when clinically indicated)
Number of subjects: 305
Study 29382793 — intervention group
Group type: COMPARATOR
Intervention: Infrequent monitoring (immediately after intubation and when clinically indicated)
Number of subjects: 305
Study 29382793 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent monitoring
Number of subjects: 305
Study 29382793 — intervention group
Group type: COMPARATOR
Intervention: Infrequent monitoring
Number of subjects: 305
Study 28865897 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stents (DES)
Number of subjects: 4626
Study 28865897 — intervention group
Group type: COMPARATOR
Intervention: Bare Metal Stents (BMS)
Number of subjects: 4626
Study 26559572 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy plus PCI (PCI group)
Number of subjects: 2287
Study 26559572 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone (medical‐therapy group)
Number of subjects: 2287
Study 26559572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PCI and medical therapy)
Number of subjects: 2287
Study 24333824 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group (RG); 12×150 minutes sessions: standard intervention + relaxation techniques
Number of subjects: 50
Study 24333824 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG); 12×90 minutes weekly sessions: psychoeducational group intervention
Number of subjects: 50
Study 24333824 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group (RG)
Number of subjects: 50
Study 24333824 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study 21402444 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 21402444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18928089 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (modified Jiawei Danggui Decection + 10 mg Loratadine tablet, once daily) for 4 weeks
Number of subjects: 47
Study 18928089 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine (10 mg Loratadine tablet, once daily) for 4 weeks
Number of subjects: 47
Study 16724174 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency (HF) rTMS over the right dorsolateral prefrontal cortex
Number of subjects: 0
Study 16724174 — intervention group
Group type: COMPARATOR
Intervention: Placebo sham condition
Number of subjects: 0
Study 12580913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized extract for 4-5 years
Number of subjects: 60
Study 12580913 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug therapy only)
Number of subjects: 60
Study 12580913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 60
Study 10781473 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg
Number of subjects: 40
Study 10781473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8622611 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassemia major patients (anti-HCV-negative)
Number of subjects: 29
Study 8622611 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassemia major patients (anti-HCV-positive)
Number of subjects: 29
Study 8622611 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hepatic cirrhosis
Number of subjects: 29
Study 8622611 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study 8622611 — intervention group
Group type: EXPERIMENTAL
Intervention: All patient groups (TM and cirrhosis)
Number of subjects: 29
Study 8622611 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassemia major patients
Number of subjects: 29
Study 1595847 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with pethidine 25 mg
Number of subjects: 60
Study 1595847 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1875% bupivacaine with pethidine 25 mg
Number of subjects: 60
Study 1595847 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with pethidine 25 mg
Number of subjects: 60
Study 6397971 — intervention group
Group type: EXPERIMENTAL
Intervention: +cyanidanol-3
Number of subjects: 99
Study 6397971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 29728331 — intervention group
Group type: COMPARATOR
Intervention: 30 mg MDMA plus psychotherapy
Number of subjects: 26
Study 29728331 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg MDMA plus psychotherapy
Number of subjects: 26
Study 29728331 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg MDMA plus psychotherapy
Number of subjects: 26
Study 29728331 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label crossover with full-dose MDMA (100-125 mg) after 30 mg
Number of subjects: 26
Study 29728331 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label crossover with full-dose MDMA (100-125 mg) after 75 mg
Number of subjects: 26
Study 29728331 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after full-dose MDMA (100-125 mg) at 12-month follow-up
Number of subjects: 26
Study 27858074 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant anchorage
Number of subjects: 30
Study 27858074 — intervention group
Group type: COMPARATOR
Intervention: Traditional intraoral anchorage
Number of subjects: 30
Study 24969368 — intervention group
Group type: EXPERIMENTAL
Intervention: Jia‐Wei‐Xiao‐Yao‐San (JWXYS)
Number of subjects: 14312
Study 24969368 — intervention group
Group type: EXPERIMENTAL
Intervention: Jia‐Wei‐Xiao‐Yao‐San (JWXYS) with Cyperus rotundus L.
Number of subjects: 14312